More than 90% of Mild to Moderate COVID-19 Patients have Strong Antibody Response
Most people with mild-to-moderate COVID-19 produce antibodies that can fight off the infection that remain at similar levels in the body for at least 5 months, suggests research carried out at Icahn School of Medicine at Mount Sinai in New York.
_______
Regeneron’s Two-Antibody COVID-19 Treatment “Cocktail” Reduces Viral Load
REGN-COV2, has met its primary endpoint of significantly reducing viral load and medical visits in ambulatory adults with COVID-19. However, the company is reviewing a possible change of dosages in the study after finding no significant difference in efficacy between the high and low doses of the treatment.
_______
Facial Masking for Covid-19 — Potential for “Variolation” as We Await a Vaccine
M. Gandhi and G.W. Rutherford N Engl J Med 2020;383:e101
_______
J.L. Schwartz N Engl J Med 2020;383:1703-1705
___________________________
CDC Releases Two New MMWRs
The first release describes an investigation of a university’s men’s and women’s soccer team where 17 COVID-19 cases were identified. Lax social distancing and mask use during social gatherings were thought to contribute to the spread.
The second release describes results from the Data Foundation’s COVID Impact Survey. Self-reported adherence to COVID-19 mitigation measures was lowest in the 18-29 age group, while those 60 years or older reported the highest adherence.
